期刊文献+

不同剂量阿司匹林联合氯吡格雷治疗老年不稳定型心绞痛疗效观察 被引量:6

Clinical effect observation of different doses of aspirin combined with clopidogrel in the treatment of elderly patients with unstable angina pectoris
下载PDF
导出
摘要 目的观察不同剂量阿司匹林联合氯吡格雷治疗老年不稳定型心绞痛的疗效。方法将不稳定型心绞痛患者150例随机分为A、B、C 3组,每组50例。分别给予阿司匹林50 mg/d、75 mg/d、100 mg/d,3组均与氯吡格雷75 mg/d双联抗血小板治疗1年,均给予标准的冠心病二级预防。比较治疗后1个月和1年内各组主要心血管事件和不良反应。结果治疗1个月时A组患者主要心血管事件发生率高于B组和C组(P<0.05),B组和C组比较差异无统计学意义(P>0.05);3组不良反应比较差异无统计学意义(P>0.05)。随访1年后发现,A、B、C3组之间主要心血管事件发生率无明显差异(P>0.05);C组轻微不良反应发生率高于A组与B组(P>0.05);但严重不良反应发生率3组之间无明显差异(P>0.05)。结论阿司匹林50 mg、75 mg联合氯吡格雷治疗老年不稳定型心绞痛安全、有效,相较100 mg的标准剂量不良反应更低,但50 mg剂量的阿司匹林在急性期(1月内)应避免使用。 Objective To observe the effect of different doses of aspirin combined with clopidogrel on the elderly patients with unstable coronary artery disease. Methods 150 patients with unstable angina were randomly divided into group A,group B,group C,50 cases in each group. The three groups were given aspirin 50mg/d,75mg/d,100mg/d,each group were treated with clopidogrel 75mg/d for one year,and three groups all given the standard secondary prevention of coronary heart disease. The incidence of major adverse cardiovascular events and adverse events were observed in one month and one year after treatment. Results After one month's treatment,the incidence of major cardiovascular events in group A was higher than group B and group C( P〈0. 05),there was no significant difference between group B and group C( P〉0. 05). There was no significant difference in adverse reaction between the three groups( P〉0. 05). After one year follow-up,there were no significant difference among the major cardiovascular events between group A,B and C( P〉0. 05); The incidence of mild adverse reactions in group C was higher than that in group A and group B( P〉0. 05),however,there was no significant difference in the incidence of serious adverse reactions among three groups( P〉0. 05). Conclusion 50 mg and 75 mg of aspirin combined with clopidogrel is a safe and effective in elderly patients with unstable angina pectoris,and is less adverse reaction than100 mg standard dose,but 50 mg of aspirin should be avoided in the acute phase( within one month).
作者 周涛 刘强 ZHOU Tao LIU Qiang(Department of Cardiology, The People's Hospital of Anyue County,Si- chuan Province ,Anyue County 642350, Chin)
出处 《临床合理用药杂志》 2017年第10期1-2,共2页 Chinese Journal of Clinical Rational Drug Use
关键词 剂量 阿司匹林 氯吡格雷 不稳定型心绞痛 Doses Aspirin Clopidogrel Unstable angina pectoris
  • 相关文献

参考文献4

二级参考文献54

  • 1曹雅旻,胡大一,吴彦,王宏宇.我国基层医院慢性心力衰竭主要原因的初步调查[J].中华内科杂志,2005,44(7):487-489. 被引量:29
  • 2李小鹰.阿司匹林在动脉硬化性心血管疾病中的临床应用:中国专家共识(2005)[J].中华心血管病杂志,2006,34(3):281-284. 被引量:194
  • 3张大真,权正良,李增烈.长期服用小剂量肠溶型阿司匹林对胃十二指肠黏膜损害的病例对照研究[J].胃肠病学,2006,11(7):427-430. 被引量:16
  • 4Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines(Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol,2002, 40(7) :1366-1374. 被引量:1
  • 5Bertrand ME, Simoons ML, Fox KA, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J,2002,23 ( 23 ) : 1809 -1840. 被引量:1
  • 6Erhardt L, Herlitz J, Bossaert L, et al. Task force on the management of chest pain. Eur Heart J, 2002, 23 ( 15 ) : 1153-1176. 被引量:1
  • 7CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet, 1996, 348(9038) :1329-1339. 被引量:1
  • 8Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med, 2001 , 345 ( 7 ) :494-502. 被引量:1
  • 9Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet, 2001, 358(9281):527-533. 被引量:1
  • 10Simoons ML, GUSTO IV-ACS Investigators. Effect of glycopmtein Ⅱb/Ⅲa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation:the GUSTO IV-ACS randomised trial. Lancet, 2001,357(9272) :1915-1924. 被引量:1

共引文献2426

同被引文献34

引证文献6

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部